REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to its huge potential in gene expression regulation.

– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Qfitlia is the sixth Alnylam-discovered ...

Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...

Codexis inks agreement with an innovator pharma company to manufacture 50 grams siRNA using its ECO Synthesis platform: Redwood City, California Friday, March 6, 2026, 11:00 Hrs [ ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines in areas of high unmet need in rare muscle diseases, ...

A formamide modification (yellow) to a therapeutic agent siRNA (blue) prevents siRNA to bind to non-target mRNA, which allows for treatment with less side effects. Small interfering RNA (siRNA) drugs ...